MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
Inovio Pharmaceuticals ROA Ratio 2011-2026 | INO
Annual ROA Ratio Inovio Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -79.04 | -80.28 | -61.23 | -30.83 | -82.92 | -73.96 | -47.11 | -42.45 | -13.65 | -27.41 | -74.79 | -43.57 | -24.96 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -13.65 | -82.92 | -52.48 |
Quarterly ROA Ratio Inovio Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -146.11 | -104.04 | -93.67 | -71.2 | -88.77 | -82.84 | -73.99 | -48.07 | -57.71 | -49.78 | -58.14 | -51.01 | -62.24 | -63.83 | -54.09 | -33.42 | -37.93 | -23.14 | -33.11 | -30.83 | -52.48 | -72.08 | -68.65 | -82.92 | -81.89 | -84.93 | -69.58 | -73.96 | -60.3 | -59.45 | -59.45 | -47.11 | -50.72 | -44.45 | -50.15 | -42.45 | -35.74 | -21.18 | -13.33 | -13.65 | -10.88 | -18.94 | -24.15 | -27.41 | -39.29 | -68.82 | -72.98 | -74.79 | -58.74 | -38.44 | -35.3 | -43.57 | -51.08 | -43.84 | -39.3 | -24.96 | -7.43 | -4.62 | -3.95 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -3.95 | -146.11 | -51.47 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
-275.96 | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M |  China |
 |
Esperion Therapeutics
ESPR
|
-4.87 | $ 3.13 | 0.55 % | $ 651 M | USA |
 |
Exelixis
EXEL
|
27.51 | $ 48.2 | 8.51 % | $ 13.1 B | USA |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Fortress Biotech
FBIO
|
3.67 | $ 2.53 | 2.85 % | $ 70.6 M | USA |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
23.87 | - | 2.54 % | $ 160 B | France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Galapagos NV
GLPG
|
-1.99 | $ 28.81 | 1.48 % | $ 2.69 B |  Belgium |
 |
Athira Pharma
ATHA
|
-114.6 | - | - | $ 269 M | USA |
 |
Genmab A/S
GMAB
|
22.5 | $ 27.95 | 1.5 % | $ 17.2 B |  Danmark |
 |
Genprex
GNPX
|
-159.75 | $ 0.91 | 2.24 % | $ 849 K | USA |
 |
Grifols, S.A.
GRFS
|
1.38 | $ 8.4 | 1.63 % | $ 6.83 B |  Spain |
 |
InflaRx N.V.
IFRX
|
-36.46 | $ 2.51 | 27.16 % | $ 152 M | Germany |
 |
Ionis Pharmaceuticals
IONS
|
-6.51 | $ 77.0 | 2.33 % | $ 12.3 B | USA |
 |
BioNTech SE
BNTX
|
65.02 | $ 94.64 | -0.9 % | $ 27.2 B | Germany |
 |
Kamada Ltd.
KMDA
|
-0.7 | $ 8.29 | 0.91 % | $ 260 M |  Israel |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
-77.89 | - | - | $ 231 M | USA |
 |
Kymera Therapeutics
KYMR
|
-17.86 | $ 85.79 | 3.72 % | $ 7.25 B | USA |
 |
Kazia Therapeutics Limited
KZIA
|
-70.51 | $ 13.58 | 0.97 % | $ 1.8 B |  Australia |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
-0.43 | $ 231.58 | -0.31 % | $ 4.24 B | USA |
 |
INmune Bio
INMB
|
-141.98 | $ 1.54 | - | $ 38.1 M | USA |
 |
Liquidia Corporation
LQDA
|
-21.02 | $ 41.64 | 3.75 % | $ 3.58 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
19.07 | $ 22.58 | 1.03 % | $ 3.74 B | USA |
 |
Mirum Pharmaceuticals
MIRM
|
-2.77 | $ 107.36 | 1.46 % | $ 5.39 B | USA |
 |
MannKind Corporation
MNKD
|
0.74 | $ 3.61 | 26.17 % | $ 1.1 B | USA |
 |
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-103.3 | $ 3.46 | -1.14 % | $ 5.7 M | Israel |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M |  Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-35.55 | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-19.87 | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
-254.37 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-11.27 | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
-76.23 | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-35.68 | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-3.73 | $ 24.0 | 2.46 % | $ 3.05 B | USA |
 |
Nanobiotix S.A.
NBTX
|
-46.19 | $ 41.6 | 19.64 % | $ 286 B | France |
 |
Allena Pharmaceuticals
ALNA
|
-140.01 | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-150.49 | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-117.57 | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-20.15 | - | - | $ 2.17 B | USA |